BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9852227)

  • 21. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
    Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
    Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
    Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
    Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
    Benhar I; Pastan I
    J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins.
    Matthey B; Engert A; Klimka A; Diehl V; Barth S
    Gene; 1999 Mar; 229(1-2):145-53. PubMed ID: 10095114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
    Wang H; Dai J; Li B; Fan K; Peng L; Zhang D; Cao Z; Qian W; Wang H; Zhao J; Guo Y
    Protein Expr Purif; 2008 Mar; 58(1):140-7. PubMed ID: 17950620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
    Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
    Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
    Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
    Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
    Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
    Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
    Nagata S; Onda M; Numata Y; Santora K; Beers R; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Jul; 8(7):2345-55. PubMed ID: 12114439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
    Brinkmann U; Lee BK; Pastan I
    J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biotechnological and gene therapeutic strategies in cancer treatment.
    Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
    Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Target-specific cytotoxic activity of recombinant fusion toxin C-CPE-ETA' against CLDN-3,4-overexpressing ovarian cancer cells].
    Yao Q; Zheng QM; Wen JF; Lü T; Wei MQ; Dai SZ
    Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):897-902. PubMed ID: 21223796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
    Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
    Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
    Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
    Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.
    Wels W; Harwerth IM; Mueller M; Groner B; Hynes NE
    Cancer Res; 1992 Nov; 52(22):6310-7. PubMed ID: 1358432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
    Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
    Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
    Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
    J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.